While the 'Outperform' rating suggests that Barrington Research expects Haemonetics to outperform the market, the lowering of the price target could indicate a tempered expectation of the stock's future performance. This could potentially lead to short-term uncertainty among investors, but the overall impact is likely to be neutral as the positive 'Outperform' rating is maintained.